Incyte, which is listed on as INCY, and Enable Injections, Inc. have announced a strategic partnership to move forward with certain therapies from Incyte’s pipeline, including its experimental monoclonal antibody that targets mutant calreticulin. This collaboration will use Enable’s enFuse On-Body Delivery System. The initial focus of the partnership is on treatments for essential thrombocythemia and myelofibrosis, with the possibility of expanding to other therapies and conditions. Incyte will have the exclusive right to use the enFuse technology with its mutCALR-targeted therapy, INCA033989. The agreement includes an upfront fee for access to the technology, potential payments for research and development and commercial success, and a cost for supplying both clinical and commercial versions of the enFuse devices.
Health Technology Insights: Roquette Launches Pharma Innovation Center to Boost Latin America as Collaborative Hub
Bill Meury, President and CEO of Incyte, said the company is always looking for ways to improve treatment experiences and patient outcomes. He noted that working with Enable brings together different areas of expertise to make advanced treatments more convenient and less demanding for patients, while still maintaining high standards of safety and effectiveness. Incyte is a leader in treating myeloproliferative neoplasms, a group of rare blood cancers that include essential thrombocythemia and myelofibrosis. INCA033989 is a first-in-class therapy that targets calreticulin mutations, which are the second most common cause of cancer-related growth in these diseases.
The enFuse system is designed to deliver large doses of biologic and small molecule drugs through the skin, offering patients an alternative to receiving treatments through intravenous infusions. Its design aims to provide a simple, discreet, and comfortable experience, allowing flexibility in where treatment takes place, including at home. This system helps patients manage their treatment with more convenience and independence, which could lead to better adherence to treatment and improved quality of life.
Health Technology Insights: Elektra Health and Oscar Launch HelloMeno Menopause Plan
Michael D. Hooven, Chairman and CEO of Enable Injections, said the partnership shows that enFuse technology is becoming a recognized solution for delivering large-volume medications under the skin. He stressed that this collaboration highlights the shared goal of both companies to enhance patient care and develop ways to deliver therapies that are easier and more comfortable for patients.
By working together, Incyte and Enable aim to combine innovative therapies with advanced delivery methods to create a more patient-focused treatment experience. Using the enFuse system with Incyte’s investigational drugs, the partnership hopes to improve access, convenience, and treatment results for patients dealing with rare blood disorders, while promoting the wider use of innovative treatment options within the healthcare system.
Health Technology Insights: Oshi Health Launches Access+ to Boost GI Practice Growth
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
